Paradigm Biopharmaceuticals Ltd (ASX:PAR) is increasing its presence at and participation in the Osteoarthritis Research Society International (OARSI) 2023 World Congress to be held in Denver, Colorado, next month.
The international conference to be held from March 17-20, 2023, is considered prestigious and will attract OA specialists from around the world with Paradigm to take part in three events.
Three events
Firstly, Paradigm, a late-stage drug development company focused on delivering new therapies to address unmet medical needs, has been invited to speak at the Clinical Trials Symposium (CTS) on Thursday, March 16, the evening before the official start of the OARSI congress.
Secondly, an abstract detailing the day 56 results from the phase 2 synovial fluid biomarker clinical trial (PARA_OA_008) has been accepted for a poster presentation at the 2023 OARSI World Congress.
This poster presentation will be conducted by Paradigm’s Dr Mukesh Ahuja, global clinical head of OA.
Oral theatre presentation
As well as these pre-arranged presentations, Paradigm has now been invited to conduct a sponsored oral theatre presentation to OARSI conference attendees.
The company’s chief scientific officer Dr Ravi Krishnan and Dr Ahuja will conduct the oral presentation which will cover Paradigm’s global OA program, including the day 56 top-line data from the PARA_OA_008 clinical trial and proposed mechanism of action.
All of this participation in the OARSI conference is recognition of Paradigm's OA clinical development programs as the event provides an opportunity for a limited number of presentations from companies in development of therapies for the treatment of osteoarthritis.
Results of OA clinical trials
Paradigm’s managing director Paul Rennie said, “It is very exciting for our company to be invited to provide an oral presentation to the OARSI Clinical Trial Symposium.
“This presentation will provide an update on our phase 3 OA clinical trial (PARA_OA_002) along with the top-line results of our disease-modifying phase 2 OA clinical trial (PARA_OA_008).
“Attendees to the CTS will hear a summary of the results from OA clinical trials over the past five years.
“Attendees at this conference are scientists and representatives from pharma companies with an interest in OA clinical trials.
“Paradigm expects to report on the six-month follow-up data from PARA_OA_008 shortly after the OARSI CTS.”
CTS Congress agenda
At the CTS Congress on March 16, the proposed agenda is:
(i) Clinical Trial Update: Lessons learned from the first five years of CTS (2017–2023, from Las Vegas to Denver). Presenting will be Virginia Byers Kraus MD, PhD, a professor in the Departments of Medicine, Pathology, and Orthopaedic Surgery, and a member of the Duke Molecular Physiology Institute (DMPI).
Dr Kraus is a practising rheumatologist with expertise in musculoskeletal research related to osteoarthritis. Her career has focused on translational research into the discovery and validation of biomarkers for early osteoarthritis detection, prediction of progression, and monitoring of disease status.
(ii) Clinical updates from selected companies in clinical development. Paradigm's chief medical officer Dr Donna Skerrett, will present the technology, mechanism of action and clinical translation of Paradigm's ongoing OA program.
The invitation to the symposium represents recognition of Paradigm's OA clinical development programs.
This event provides an opportunity for a limited number of presentations from companies developing therapies for the treatment of osteoarthritis.
About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing and delivering pharmaceutical therapies.
The company’s current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).